News

Recent news about Panacea Capital and select portfolio companies

December 10, 2025

Chime Biologics Announces Strategic Collaboration with Beijing Libang Pharmaceutical on Global Blinatumomab Biosimilar Program

December 10, 2025

Chime Biologics Announces Strategic Collaboration with Beijing Libang Pharmaceutical on Global Blinatumomab Biosimilar Program

December 9, 2025

Chime Biologics Announces Strategic Collaboration with TNAX Biopharma, Marking Its First Partnership in Japan

December 9, 2025

Chime Biologics Announces Strategic Collaboration with TNAX Biopharma, Marking Its First Partnership in Japan

November 13, 2025

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer

November 13, 2025

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer

November 11, 2025

Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors

Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.

November 11, 2025

Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors

Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.

October 28, 2025

Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors

October 28, 2025

Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors